Dr. Iyengar on the Benefit of Trastuzumab Deruxtecan in Metastatic HER2+ Breast Cancer After T-DM1
Neil M. Iyengar, MD, discusses the expanding investigation and role of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer.
Neil M. Iyengar, MD, discusses the expanding investigation and role of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer.
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses how advancements in precision medicine have improved outcomes for patients with brain metastases.
The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
In acute myeloid leukemia, investigators are exploring novel agents engineered to target adhesion factors, which can mobilize persistent leukemic stem cells from the bone marrow…
Oncologists present the clinical scenario of a 65-year-old woman with recurrent HR-positive, HER2-low breast cancer, and discuss optimal sequencing of systemic therapies in this setting.
Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.
The United States Preventive Services Task Force final breast cancer screening recommendation statement advises that women aged 40 begin biennial screening.
Neli Ulrich, PhD, MS, of Huntsman Cancer Institute, has been awarded the 2024 Governor’s Medal for Science and Technology.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.